(Q40431366)

20 September 2017

Pharmacokinetic and pharmacodynamic study of intratumoral injection of an adenovirus encoding endostatin in patients with advanced tumors (English)

1 reference

20 September 2017

1 reference

1 reference

1 reference

Li HL

1

1 reference

20 September 2017

Li S

2

1 reference

20 September 2017

Shao JY

3

1 reference

20 September 2017

Lin XB

4

1 reference

20 September 2017

Cao Y

5

1 reference

20 September 2017

Jiang WQ

6

1 reference

20 September 2017

Liu RY

7

1 reference

20 September 2017

Zhao P

8

1 reference

20 September 2017

Zhu XF

9

1 reference

20 September 2017

Zeng MS

10

1 reference

20 September 2017

Guan ZZ

11

1 reference

20 September 2017

Huang W

12

1 reference

20 September 2017

20 December 2007

1 reference

20 September 2017

1 reference

20 September 2017

15

1 reference

20 September 2017

4

1 reference

20 September 2017

247-256

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.gt.3303038

20 September 2017

0 references

cites work

Tumorigenesis and the angiogenic switch

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303038

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303038

Control of angiogenesis with synthetic heparin substitutes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303038

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303038

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303038

Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303038

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303038

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303038

Endostatin action and intracellular signaling: beta-catenin as a potential target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303038

Endostatin's antiangiogenic signaling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303038

Synergistic anti-tumor effect of recombinant human endostatin adenovirus combined with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303038

Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303038

Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303038

Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303038

Dynamic distribution and expression in vivo of human endostatin gene delivered by adenoviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303038

Endostatin: the logic of antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303038

Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303038

Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303038

Adenovirus-mediated intra-tumoral delivery of the human endostatin gene inhibits tumor growth in nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303038

7 January 2021

Phase I study of recombinant human endostatin in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303038

7 January 2021

Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303038

7 January 2021

Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303038

7 January 2021

Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303038

7 January 2021

Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303038

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3303038

1 reference

Dimensions Publication ID

20 September 2017

0 references

1 reference